{"name":"Shouyao Holdings (Beijing) Co. LTD","slug":"shouyao-holdings-beijing-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"SY-3505 Capsules","genericName":"SY-3505 Capsules","slug":"sy-3505-capsules","indication":"Type 2 diabetes","status":"phase_3"},{"name":"SY-5007","genericName":"SY-5007","slug":"sy-5007","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Crizotinib Capsules","genericName":"Crizotinib Capsules","slug":"crizotinib-capsules","indication":"ALK-positive metastatic non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"Crizotinib Capsules","genericName":"Crizotinib Capsules","slug":"crizotinib-capsules","phase":"phase_3","mechanism":"Crizotinib is a tyrosine kinase inhibitor that blocks ALK (anaplastic lymphoma kinase) and ROS1 signaling to inhibit cancer cell growth.","indications":["ALK-positive metastatic non-small cell lung cancer","ROS1-positive metastatic non-small cell lung cancer"],"catalyst":""},{"name":"SY-3505 Capsules","genericName":"SY-3505 Capsules","slug":"sy-3505-capsules","phase":"phase_3","mechanism":"SY-3505 Capsules is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"SY-5007","genericName":"SY-5007","slug":"sy-5007","phase":"phase_3","mechanism":"SY-5007 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQb2E0a0lDZ3Rybk5fZkpVVmdDR280YmtPa2JRNDlXZzFIa3d4QWZjT2lMbEF5R3lCVDJCS3pkdjA3MFZxUEtqZlBoZ2JjUXcyNE8zTkNtNEVpc2Jua2wwNnVaMWlyVFYxWmZpVUJuODBtWm4zX04xSXFUMXpKcXJhUVBCTzJ0YnBneTB4MFFRUGVrNmNRWWQzTTNfRlY1UE9VYjZYMkRla3B3SzhidFpENTlDYUxKZUh4dHd3?oc=5","date":"2026-04-06","type":"pipeline","source":"Markets Mojo","summary":"Shouyao Holdings Hits Day Low of CNY 36.42 Amid Price Pressure - Markets Mojo","headline":"Shouyao Holdings Hits Day Low of CNY 36.42 Amid Price Pressure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQOG5sZEpjUzZkYzhvUUl0YVh3QjFuTVdsREQ0SnB0X0trN0NEbmw0Z2ZnZ296dWhQalE1OFNIdHZGYUZ2Q0lIQTQxUElFNWlnbU11dFJWcVQ5Wk12ZWpQaGJyVUZSWnB4NFA0ZXR3TXNIZVNXTFNGb0MtMEl2OC1BaE1NV2xKVnhHM0xJYmpnNVZ5eWUxbDlFczdDaGR3RGV2QlQ0THZkM0RuZ29qZW1kMjcyVGI?oc=5","date":"2024-04-12","type":"pipeline","source":"Seeking Alpha","summary":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD) - Seeking Alpha","headline":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD)","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}